PHOTOCURE
Research PHOTOCURE (PHO.OL) on Bullrun: market cap NOK 1.33B, P/E 17.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHO.OL
- ExchangeXOSL
- CountryNorway
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyNOK
- Market capNOK 1.33B
- P/E17.0
- Financial periodQ2 2026
- RevenueNOK 142.48M
- Net income-NOK 709.00K
- Free cash flowNOK 57.60M
- Gross margin92.7%
Valuation Snapshot
latest market cap is NOK 1.33B; P/E is 17.0.
Peer valuation comparison
Latest P/E is 16.98x versus a Healthcare sector median of 24.6x (31.0% below).
Latest P/E is 16.98x versus a Norway median of 14.52x (16.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | NOK 525.39M | -NOK 3.34M | NOK 65.30M | 94.2% | -0.12 | NOK 293.85M | NOK 15.78M | NOK 501.72M |
| FY2023 | NOK 500.66M | NOK 979.00K | NOK 36.00M | 94.8% | 0.04 | NOK 259.50M | NOK 14.02M | NOK 482.85M |
| FY2022 | NOK 393.13M | -NOK 71.86M | -NOK 5.63M | 94.2% | -2.66 | NOK 268.07M | NOK 27.38M | NOK 462.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | NOK 1.33B | 17.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 NOK.
About PHOTOCURE
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PHOTOCURE's market cap?
PHOTOCURE's market capitalization is NOK 1.33B.
What is PHOTOCURE's P/E ratio?
PHOTOCURE's price-to-earnings (P/E) ratio is 17.0.
What does PHOTOCURE do?
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.